Clinical Trial Update: Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 [Phase 3]

View source ↗

Summary

Phase 3 study comparing cabozantinib to prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Prostate Cancer, Castration Resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-03-14